Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Cash & Equivalents (2016 - 2026)

Dexcom has reported Cash & Equivalents over the past 17 years, most recently at $1.1 billion for Q1 2026.

  • Quarterly Cash & Equivalents rose 23.57% to $1.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Mar 2026, up 23.57% year-over-year, with the annual reading at $392.8 million for FY2025, 192.7% up from the prior year.
  • Cash & Equivalents was $1.1 billion for Q1 2026 at Dexcom, up from $392.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $1.4 billion in Q3 2025 and troughed at $134.2 million in Q4 2024.
  • The 5-year median for Cash & Equivalents is $698.1 million (2022), against an average of $750.9 million.
  • Year-over-year, Cash & Equivalents crashed 76.3% in 2024 and then skyrocketed 192.7% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $642.3 million in 2022, then fell by 11.83% to $566.3 million in 2023, then crashed by 76.3% to $134.2 million in 2024, then skyrocketed by 192.7% to $392.8 million in 2025, then skyrocketed by 184.67% to $1.1 billion in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Cash & Equivalents are $1.1 billion (Q1 2026), $392.8 million (Q4 2025), and $1.4 billion (Q3 2025).